Liu Xianglin, Liu Wenqiang, Wu Yuting, Wang Yichuan, Jiang Qingliang, Li Yangyang, Li Hengyu, Hao Liqiang
Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Department of Urology, Changhai Hospital, Navel Medical University (Second Military Medical University), Shanghai, China.
Sci Rep. 2025 May 25;15(1):18275. doi: 10.1038/s41598-025-03713-1.
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, necessitating the development of novel therapeutic strategies. We explore the expression characteristics of SLC39A6 in CRC by combining multiple cohorts and multi-omics. The therapeutic effect and potential mechanism of BRY812 on CRC were explored through in vitro experiments. Our research results show that the expression of SLC39A6 in CRC tissues is higher than that in normal tissues, and it is closely related to tumor pathways, making it a good therapeutic target. BRY812 has an inhibitory effect on the growth, migration and stemness of CRC cells, and may exert its killing effect by downregulating the AKT pathway. This study has identified SLC39A6 as a potential therapeutic target in CRC. BRY812 is expected to become a highly promising therapeutic drug, bringing new hope to patients with CRC.
结直肠癌（CRC）是全球癌症相关死亡的主要原因之一，因此需要开发新的治疗策略。我们通过整合多个队列和多组学数据来探究SLC39A6在结直肠癌中的表达特征。通过体外实验研究了BRY812对结直肠癌的治疗效果及其潜在机制。我们的研究结果表明，SLC39A6在结直肠癌组织中的表达高于正常组织，且与肿瘤通路密切相关，使其成为一个良好的治疗靶点。BRY812对结直肠癌细胞的生长、迁移和干性具有抑制作用，可能通过下调AKT通路发挥其杀伤作用。本研究已确定SLC39A6是结直肠癌的一个潜在治疗靶点。BRY812有望成为一种极具前景的治疗药物，为结直肠癌患者带来新的希望。
